Real-world use of ranibizumab for neovascular age-related macular degeneration in Taiwan
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2045-2322
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Real-world use of ranibizumab for neovascular age-related macular degeneration in Taiwan ; volume:8 ; number:1 ; day:10 ; month:5 ; year:2018 ; pages:1-11 ; date:12.2018
Scientific reports ; 8, Heft 1 (10.5.2018), 1-11, 12.2018
- Urheber
-
Chang, Yi-Sheng
- Beteiligte Personen und Organisationen
-
Lee, Wan-Ju
Lim, Chen-Chee
Wang, Shih-Hao
Hsu, Sheng-Min
Chen, Yi-Chian
Cheng, Chia-Yi
Teng, Yu-Ti
Huang, Yi-Hsun
Lai, Chun-Chieh
Tseng, Sung-Huei
SpringerLink (Online service)
- DOI
-
10.1038/s41598-018-25864-0
- URN
-
urn:nbn:de:101:1-2018070800473040980005
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:28 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Chang, Yi-Sheng
- Lee, Wan-Ju
- Lim, Chen-Chee
- Wang, Shih-Hao
- Hsu, Sheng-Min
- Chen, Yi-Chian
- Cheng, Chia-Yi
- Teng, Yu-Ti
- Huang, Yi-Hsun
- Lai, Chun-Chieh
- Tseng, Sung-Huei
- SpringerLink (Online service)
Ähnliche Objekte (12)
Macular functional changes in patients with neovascular age-related macular degeneration receiving ranibizumab therapy (lucentis)
Cost-Effectiveness Analysis of Ranibizumab Biosimilar for Neovascular Age-Related Macular Degeneration in Japan
Correction: Cost-Effectiveness Analysis of Ranibizumab Biosimilar for Neovascular Age-Related Macular Degeneration in Japan
Peripapillary choroidal thickness after intravitreal ranibizumab injections in eyes with neovascular age-related macular degeneration
Efficacy and safety of intravitreal aflibercept in ranibizumab-refractory patients with neovascular age-related macular degeneration
Beneficial switch from aflibercept to ranibizumab for the treatment of refractory neovascular age-related macular degeneration
Bevacizumab and ranibizumab for neovascular age-related macular degeneration: an updated meta-analysis of randomised clinical trials
Macular Hole Formation Following Intravitreal Aflibercept for Neovascular Age-Related Macular Degeneration
Near-infrared reflectance imaging of neovascular age-related macular degeneration
Mineralocorticoid Antagonists as Adjuncts in Neovascular Age-Related Macular Degeneration
The comparative effectiveness and cost-effectiveness of ranibizumab for neovascular macular degeneration revisited
Prognostic factors for long term visual acuity outcome after Ranibizumab Therapy in patients with neovascular age-related macular degeneration
Macular functional changes in patients with neovascular age-related macular degeneration receiving ranibizumab therapy (lucentis)
Cost-Effectiveness Analysis of Ranibizumab Biosimilar for Neovascular Age-Related Macular Degeneration in Japan
Correction: Cost-Effectiveness Analysis of Ranibizumab Biosimilar for Neovascular Age-Related Macular Degeneration in Japan
Peripapillary choroidal thickness after intravitreal ranibizumab injections in eyes with neovascular age-related macular degeneration
Efficacy and safety of intravitreal aflibercept in ranibizumab-refractory patients with neovascular age-related macular degeneration
Beneficial switch from aflibercept to ranibizumab for the treatment of refractory neovascular age-related macular degeneration
Bevacizumab and ranibizumab for neovascular age-related macular degeneration: an updated meta-analysis of randomised clinical trials
Macular Hole Formation Following Intravitreal Aflibercept for Neovascular Age-Related Macular Degeneration
Near-infrared reflectance imaging of neovascular age-related macular degeneration
Mineralocorticoid Antagonists as Adjuncts in Neovascular Age-Related Macular Degeneration
The comparative effectiveness and cost-effectiveness of ranibizumab for neovascular macular degeneration revisited
Prognostic factors for long term visual acuity outcome after Ranibizumab Therapy in patients with neovascular age-related macular degeneration
Macular functional changes in patients with neovascular age-related macular degeneration receiving ranibizumab therapy (lucentis)
Cost-Effectiveness Analysis of Ranibizumab Biosimilar for Neovascular Age-Related Macular Degeneration in Japan
Correction: Cost-Effectiveness Analysis of Ranibizumab Biosimilar for Neovascular Age-Related Macular Degeneration in Japan
Peripapillary choroidal thickness after intravitreal ranibizumab injections in eyes with neovascular age-related macular degeneration
Efficacy and safety of intravitreal aflibercept in ranibizumab-refractory patients with neovascular age-related macular degeneration
Beneficial switch from aflibercept to ranibizumab for the treatment of refractory neovascular age-related macular degeneration
Bevacizumab and ranibizumab for neovascular age-related macular degeneration: an updated meta-analysis of randomised clinical trials
Macular Hole Formation Following Intravitreal Aflibercept for Neovascular Age-Related Macular Degeneration
Near-infrared reflectance imaging of neovascular age-related macular degeneration
Mineralocorticoid Antagonists as Adjuncts in Neovascular Age-Related Macular Degeneration
The comparative effectiveness and cost-effectiveness of ranibizumab for neovascular macular degeneration revisited